Cell viability analysis showed that ATF6 inhibitors alone efficiently suppressed GIST cell growth, irrespective of imatinib resistance, while the antitumor effect was synergistically enhanced when the ATF6 inhibitors are combined with ER stress-inducing drugs. The gene discussed is ATF6; the disease is gastrointestinal stromal tumor.